Corcept Therapeutics Inc’s recent filing unveils that its Chief Development Officer Guyer William unloaded Company’s shares for reported $1.6 million on Dec 02 ’25. In the deal valued at $80.08 per share,20,000 shares were sold. As a result of this transaction, Guyer William now holds 1,235 shares worth roughly $86684.65.
Then, Maduck Sean sold 20,000 shares, generating $1,590,490 in total proceeds. Upon selling the shares at $79.52, the insider now owns 7,904 shares.
Before that, Lyon Joseph Douglas sold 5,000 shares. Corcept Therapeutics Inc shares valued at $397,632 were divested by the insider at a price of $79.53 per share. As a result of the transaction, Lyon Joseph Douglas now holds 10,277 shares, worth roughly $0.72 million.
UBS initiated its Corcept Therapeutics Inc [CORT] rating to a Neutral in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”a Peer perform”‘ rating. Truist also remained covering CORT and has increased its forecast on November 06, 2023 with a “Buy” recommendation from previously “Hold” rating. SVB Securities started covering the stock on April 11, 2023. It rated CORT as “a Market perform”.
Price Performance Review of CORT
On Tuesday, Corcept Therapeutics Inc [NASDAQ:CORT] saw its stock fall -12.06% to $70.19. Over the last five days, the stock has lost -17.52%. Corcept Therapeutics Inc shares have risen nearly 30.89% since the year began. Nevertheless, the stocks have risen 39.30% over the past one year. While a 52-week high of $117.33 was reached on 03/31/25, a 52-week low of $49.00 was recorded on 01/13/25.
Levels Of Support And Resistance For CORT Stock
The 24-hour chart illustrates a support level at 66.82, which if violated will result in even more drops to 63.45. On the upside, there is a resistance level at 76.66. A further resistance level may holdings at 83.13.
How much short interest is there in Corcept Therapeutics Inc?
A steep rise in short interest was recorded in Corcept Therapeutics Inc stocks on 2025-12-15, dropping by 58014.0 shares to a total of 10.11 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 10.17 million shares. There was a decline of -0.57%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on April 04, 2023 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $27 price target.
